We describe a case of a 49-year-old, male, Caucasian, pharmaco-resistant patient with a recurrent major depressive disorder, who developed acute pulmonary embolism during a course of inpatient rightunilateral ultra-brief electroconvulsive therapy. After the stabilization of his somatic condition, we were able to safely continue with further ECT applications until his mood normalized and he was able to return to his normal life outside the hospital. Case reports on this topic are scarce e our article demonstrates that electroconvulsive treatment, with proper precautionary measures (anti-aggregative or anti-coagulation prophylaxis) is safe and can be administered without unnecessary delay. B. J et al. / Brain Stimulation xxx (xxxx) xxx 2 Please cite this article as: J B et al., A case report of pulmonary embolism during electroconvulsive therapy and its further application after somatic stabilization, Brain Stimulation, https://doi.
Introduction
Electroconvulsive therapy (ECT) is a safe and effective treatment modality used in a broad range of neuropsychiatric conditions. Despite this fact supported by an overwhelming number of studies, not many reports have been published regarding the safety of this method in patients with pulmonary embolism (PE) or reports that describe PE as a rare adverse effect of ECT. In this article, we present an unusual case of a patient who developed a non-fatal pulmonary embolism during an acute phase of ECT treatment at our department and subsequently continued with further ECT sessions after his somatic condition was stabilized.
Case presentation
Mr. N. is a 49-year-old, obese (BMI 31) male, right-handed Caucasian patient who was admitted to our department with a recurrent major depressive disorder. 2 months prior to his hospitalization, he was medicated with 150mg of trazodone as an outpatient, without any effect. Upon admission, his mood was severely depressive e scoring 35 points on the Montgomery-Asberg Depression Rating Scale (MADRS), SDS index 79 on the Zung Self-Depression Rating Scale (ZSDRS) and 60 points on the Beck Anxiety Inventory (BAI). He was not treated for any somatic condition, had a physiological bloodwork and ECG upon admission. Pharmacological treatment was re-evaluated and the patient was switched to a combination of venlafaxine and mirtazapine -titrated to 300mg and 30mg respectively for 2 weeks with minimal effect e he remained severely depressed, had complaints of dyssomnia and intermittent anxiety attacks. The patient was offered the option to undergo ECT, to which he agreed and signed an informed consent. Thrombosis prophylaxis was considered due to the presence of obesity and lowered mobility (consequence of his depressed mood). In the end, we did not administer any anticoagulation or anti-aggregation medication, because currently, electroconvulsive therapy is not viewed upon as a risk factor for PE. He was classified as ASA 1 (American Society of Anesthesiologists). He did not have any family history of venous thrombotic embolism (VTE), pulmonary embolism or coagulation disorder of any type.
The seizure threshold (ST) was titrated with the following parameters (right-unilateral placement of electrodes, MECTA spEC-Trum™ 5000Q, frequency 20 Hz, duration 4 s, pulse width 0.3 ms, current 800 mA, charge 38.4mC) during his first session, with a seizure lasting 10 s clinically and an EEG endpoint of 18 s. We followed up with the application of 6x ST (230.4 mC, 60 Hz, 8s, 0.3 ms, 800 mA) 3 times a week, that resulted in therapeutic seizures lasting 22e30 s. General anesthesia was induced by 120 mg of propofol and myorelaxation by 30 mg of succinylcholine prior to each session. Both his mood and sleep were improving at a rapid rate and the sessions were without any observable adverse effects.
In the evening following the 4th application (within 5 hours after the session), the patient started to complain about shortness of breath that was first attributed to anxiety. However, this symptom was worsening over the next 24 hours and the patient eventually developed a sore cough, complained about permanent chesttightness and was running out of breath during a regular conversation. This was followed up by an extensive somatic examination e his O2 saturation was at 82% and blood work revealed a pathological increase of D-dimers (4590 mg/l) and troponin (209 ng/l).
Computed Tomography Angiography (CTA) was performed, confirming an intermediate-high risk bilateral pulmonary embolism with signs of right-sided cardiac overload and the patient was transferred for treatment to an intensive care unit (ICU).
Mr. N. was successfully treated with unfractionated heparin, that was eventually switched to low molecular weight heparin (LMWH) and finally dabigatran. The source of the clot was not identified, ultrasonography of the lower extremities did not reveal phlebothrombosis. The patient was eventually transferred back to our department after 10 days on ICU with the following medication e dabigatran 300 mg, mirtazapine 30 mg and venlafaxine 300 mg. He was once again referring dyssomnia, his mood remained depressed, but significantly improved when compared to admission. Mr.N. scored 26 points on MADRS, SDS index of 60 on ZSDRS and 40 points on BAI.
Because of the major effect of ECT on the depression, after careful consideration and interdisciplinary consultation, we deemed that the benefit of ECT outweighed the potential risk and decided to continue with this treatment. Mr.N. agreed and signed consent to continue with ECT. The patient underwent 4 more ECT applications, using the same parameters (MECTA spECTrum™ 5000Q 230.4 mC, 60 Hz, 8 s, 0.3 ms, 800 mA) and the application of 120 mg of propofol and 30 mg of succinylcholine before each session. These resulted in seizures lasting 18e25 s, without any observable adverse effects. His mood and sleep rapidly normalized and the patient was eventually discharged in a stable condition with a MADRS score of 6, SDS index of 48 on ZDRS and 15 points on BAI.
Discussion
Reports on the relationship between ECT and PE are scarce. They can be divided into three main categories e fatal case reports of pulmonary embolism manifesting shortly after electroconvulsive therapy [2, 10] , non-fatal case reports of PE after ECT and finally [4, 6] , reports of patients who underwent this form of treatment with previously known PE [1, 7, 9] .
Our report is unusual in the aspect that we describe a patient who most likely developed non-fatal acute PE during an inpatient ECT course and was then successfully treated with the same modality after his somatic condition stabilized.
It is difficult to establish the exact relationship between ECT and PE in our patient. The rapid onset of symptoms after the 4th session could indicate that the generalized seizure provoked a dislodgement of a pre-existing clot in the periphery by muscle spasms, despite myorelaxation. This mechanism was already proposed by Mamah et al., in 2005 [4] . Similar to the patient described in their case report, Mr. N. also had several risk factors for venous stasis present e obesity, depression and physical inactivity. However, he was not treated for any somatic condition and classified as ASA 1.
Another important factor that should be mentioned is the use of antidepressant medication e it has been associated with a higher risk of developing PE or VTE in several studies. It was suggested that the risk of VTE is higher in the first weeks of use [5] . Mr.N. had a new antidepressant medication upon admission, therefore we cannot rule out its effect on PE development.
It is worthwhile mentioning that VTE and PE are often asymptomatic conditions. Therefore, it is important to make a risk assessment in each individual patient before ECT [8] , for example by using the Rogers Score System [3] . Individuals who are found to be at higher risk could benefit from the usage of LWMH before each ECT session.
Finally, we cannot rule out the possibility that the occurrence of PE after ECT was coincidental. There is only a handful of articles on this topic currently available and the rarity of this adverse effect is most likely going to make it impossible to conduct any type of a randomized control trial.
Conclusion
Limited data is available on the topic of relationship between pulmonary embolism and electroconvulsive therapy. Based on our and previous case reports, we can conclude that pulmonary embolism as an adverse effect is a very rare occurrence, that is difficult to predict. Further articles on this topic might help to create a stratification and scoring system for patients who are at a higher risk, that could benefit from anti-aggregation or anti-coagulation medication use before initiating ECT. We present another case report of safe administration of ECT in a patient with pulmonary embolism. Mr.N. was able to return to his normal life outside the hospital after several unsuccessful psycho-pharmacological interventions.
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